TY -的T1 -普瑞巴林在中央与脊髓损伤相关的神经性疼痛JF -神经学乔-神经病学SP - 1792 LP - 1800——10.1212/01. wnl.0000244422.4527首页8。ff六世- 67 - 10 AU - p . j .西达盟m . j .兄弟盟——a . Otte AU - t .葛瑞斯AU - r·钱伯斯AU - t·k·墨菲Y1 - 2006/11/28 UR - //www.ez-admanager.com/content/67/10/1792.abstrac首页t N2 -目的:评估与中部的神经性疼痛与脊髓损伤有关。方法:12周,多中心研究的患者随机要么flexible-dose普瑞巴林150到600毫克/天(n = 70)或安慰剂(n = 67),进行报价。病人被允许保留在现有的稳定的疼痛治疗。主要疗效变量是端点代表痛苦得分,来自病人的最后7天每天疼痛日记。关键二次端点包括疼痛应答率,SF-MPQ,睡眠干扰,情绪,和病人全球的变化。结果:平均基线与组疼痛评分是6.54和6.73在安慰剂组。意味着端点与组的疼痛评分较低比安慰剂组(4.62)(6.27;p & lt;0.001),疗效观察早在第一周期间和维护。 The average pregabalin dose after the 3-week stabilization phase was 460 mg/day. Pregabalin was significantly superior to placebo in endpoint assessments on the SF-MPQ. The ≥30% and ≥50% pain responder rates were higher with pregabalin than placebo (p < 0.05). Pregabalin was associated with improvements in disturbed sleep (p < 0.001) and anxiety (p < 0.05), and more patients reported global improvement at endpoint in the pregabalin group (p < 0.001). Mild or moderate, typically transient, somnolence and dizziness were the most common adverse events. Conclusions: Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury. ER -